Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.25 USD | -3.68% | -3.35% | -34.43% |
31/05 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
24/05 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.43% | 494.56Cr | |
-2.29% | 8.94TCr | |
-3.95% | 3.79TCr | |
-13.07% | 3.2TCr | |
+63.05% | 2.6TCr | |
-22.14% | 1.41TCr | |
-7.96% | 1.29TCr | |
-9.33% | 1.18TCr | |
-46.33% | 1.09TCr | |
+5.77% | 891.58Cr |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals Insider Sold Shares Worth $444,620, According to a Recent SEC Filing